
Groundâbreaking PhaseâŊ3 results for olezarsen in severe hypertriglyceridemia unveiled at AHA Scientific Sessions
Ionis Pharmaceuticals, Inc. has announced pivotal data from its PhaseâŊ3 CORE and CORE2 studies of olezarsen in patients with severe hypertriglyceridem...















































